For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $51.05 in the last session, up 5.15% from day before closing price of $48.55. In other words, the price has increased by $5.15 from its previous closing price. On the day, 1.78 million shares were traded.
Ratios:
We take a closer look at MLTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
Goldman Upgraded its Neutral to Buy on January 17, 2025, whereas the target price for the stock was revised from $62 to $82.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 04 ’24 when BVF PARTNERS L P/IL sold 2,000,000 shares for $50.00 per share. The transaction valued at 100,003,200 led to the insider holds 1,287,768 shares of the business.
Sturge Simon sold 171,000 shares of MLTX for $9,186,120 on Oct 04 ’24. The Director now owns 171,980 shares after completing the transaction at $53.72 per share.
Stock Price History:
Over the past 52 weeks, MLTX has reached a high of $58.26, while it has fallen to a 52-week low of $31.42. The 50-Day Moving Average of the stock is 30.99%, while the 200-Day Moving Average is calculated to be 11.75%.
Shares Statistics:
A total of 63.47M shares are outstanding, with a floating share count of 52.94M. Insiders hold about 16.60% of the company’s shares, while institutions hold 94.76% stake in the company.
